Drug data last refreshed 17h ago · AI intelligence enriched 6d ago
Levothyroxine Sodium is a synthetic thyroid hormone replacement therapy administered intravenously as a solution. It is used to treat hypothyroidism and other thyroid hormone deficiency conditions. The drug works by supplementing or replacing insufficient endogenous thyroid hormone production.
Product is at peak commercial phase with moderate competitive pressure (30), suggesting stable revenue streams and established field teams.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
Fasting Study of Levothyroxine Sodium Tablets 300 mcg to Synthroid® Tablets 300 mcg
Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg
Worked on LEVOTHYROXINE SODIUM at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLevothyroxine Sodium represents a stable, established product at peak commercial maturity with moderate competitive intensity. Career opportunities center on defending market position and managing the upcoming LOE transition over the next decade.